|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PLG |
Gene summary for PLG |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PLG | Gene ID | 5340 |
| Gene name | plasminogen | |
| Gene Alias | HAE4 | |
| Cytomap | 6q26 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | P00747 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5340 | PLG | NAFLD1 | Human | Liver | NAFLD | 2.69e-16 | 1.45e+00 | -0.04 |
| 5340 | PLG | S41 | Human | Liver | Cirrhotic | 2.20e-08 | 8.92e-01 | -0.0343 |
| 5340 | PLG | S42 | Human | Liver | HCC | 2.55e-03 | 6.10e-01 | -0.0103 |
| 5340 | PLG | S43 | Human | Liver | Cirrhotic | 1.65e-06 | 1.62e-01 | -0.0187 |
| 5340 | PLG | HCC1_Meng | Human | Liver | HCC | 6.67e-115 | 4.79e-01 | 0.0246 |
| 5340 | PLG | HCC2_Meng | Human | Liver | HCC | 2.59e-11 | -3.90e-01 | 0.0107 |
| 5340 | PLG | cirrhotic1 | Human | Liver | Cirrhotic | 1.79e-09 | -3.46e-01 | 0.0202 |
| 5340 | PLG | cirrhotic2 | Human | Liver | Cirrhotic | 4.94e-10 | -2.99e-01 | 0.0201 |
| 5340 | PLG | cirrhotic3 | Human | Liver | Cirrhotic | 1.53e-03 | -3.62e-01 | 0.0215 |
| 5340 | PLG | HCC1 | Human | Liver | HCC | 2.47e-44 | 5.98e+00 | 0.5336 |
| 5340 | PLG | HCC2 | Human | Liver | HCC | 1.05e-26 | 3.63e+00 | 0.5341 |
| 5340 | PLG | Pt13.a | Human | Liver | HCC | 6.81e-09 | -1.08e-01 | 0.021 |
| 5340 | PLG | Pt13.b | Human | Liver | HCC | 8.49e-09 | -2.65e-01 | 0.0251 |
| 5340 | PLG | Pt14.a | Human | Liver | HCC | 1.55e-06 | 1.26e-02 | 0.0169 |
| 5340 | PLG | Pt14.b | Human | Liver | HCC | 1.33e-08 | -3.04e-02 | 0.018 |
| 5340 | PLG | Pt14.d | Human | Liver | HCC | 8.30e-07 | -1.70e-01 | 0.0143 |
| 5340 | PLG | S016 | Human | Liver | HCC | 4.69e-10 | -3.51e-01 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00706131 | Liver | HCC | regulation of protein processing | 37/7958 | 65/18723 | 1.33e-02 | 4.77e-02 | 37 |
| GO:004586220 | Oral cavity | OSCC | positive regulation of proteolysis | 236/7305 | 372/18723 | 6.53e-22 | 1.38e-19 | 236 |
| GO:005160410 | Oral cavity | OSCC | protein maturation | 170/7305 | 294/18723 | 3.97e-11 | 1.28e-09 | 170 |
| GO:00164856 | Oral cavity | OSCC | protein processing | 121/7305 | 225/18723 | 4.56e-06 | 5.23e-05 | 121 |
| GO:19033172 | Oral cavity | OSCC | regulation of protein maturation | 36/7305 | 67/18723 | 1.01e-02 | 3.51e-02 | 36 |
| GO:00706132 | Oral cavity | OSCC | regulation of protein processing | 35/7305 | 65/18723 | 1.07e-02 | 3.64e-02 | 35 |
| GO:0045862110 | Oral cavity | LP | positive regulation of proteolysis | 165/4623 | 372/18723 | 5.40e-17 | 8.46e-15 | 165 |
| GO:005160416 | Oral cavity | LP | protein maturation | 122/4623 | 294/18723 | 1.37e-10 | 7.72e-09 | 122 |
| GO:001648513 | Oral cavity | LP | protein processing | 83/4623 | 225/18723 | 2.87e-05 | 4.52e-04 | 83 |
| GO:190331711 | Oral cavity | LP | regulation of protein maturation | 29/4623 | 67/18723 | 6.51e-04 | 5.90e-03 | 29 |
| GO:007061311 | Oral cavity | LP | regulation of protein processing | 28/4623 | 65/18723 | 8.77e-04 | 7.59e-03 | 28 |
| GO:00316383 | Oral cavity | LP | zymogen activation | 26/4623 | 60/18723 | 1.19e-03 | 9.62e-03 | 26 |
| GO:004586229 | Skin | cSCC | positive regulation of proteolysis | 169/4864 | 372/18723 | 2.43e-16 | 2.21e-14 | 169 |
| GO:005160419 | Skin | cSCC | protein maturation | 117/4864 | 294/18723 | 1.27e-07 | 2.93e-06 | 117 |
| GO:00164858 | Skin | cSCC | protein processing | 79/4864 | 225/18723 | 1.43e-03 | 9.02e-03 | 79 |
| GO:0045862113 | Thyroid | PTC | positive regulation of proteolysis | 198/5968 | 372/18723 | 6.68e-18 | 6.91e-16 | 198 |
| GO:005160420 | Thyroid | PTC | protein maturation | 132/5968 | 294/18723 | 1.71e-06 | 2.39e-05 | 132 |
| GO:00164859 | Thyroid | PTC | protein processing | 95/5968 | 225/18723 | 6.60e-04 | 4.15e-03 | 95 |
| GO:00107554 | Thyroid | PTC | regulation of plasminogen activation | 9/5968 | 13/18723 | 6.33e-03 | 2.79e-02 | 9 |
| GO:004586234 | Thyroid | ATC | positive regulation of proteolysis | 202/6293 | 372/18723 | 1.07e-16 | 9.42e-15 | 202 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
| hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
| hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
| hsa0516410 | Liver | Cirrhotic | Influenza A | 66/2530 | 171/8465 | 8.56e-03 | 2.91e-02 | 1.79e-02 | 66 |
| hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
| hsa0516411 | Liver | Cirrhotic | Influenza A | 66/2530 | 171/8465 | 8.56e-03 | 2.91e-02 | 1.79e-02 | 66 |
| hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| hsa0516421 | Liver | HCC | Influenza A | 101/4020 | 171/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 101 |
| hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| hsa0516431 | Liver | HCC | Influenza A | 101/4020 | 171/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 101 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| PLG | F2R | PLG_F2R | PARs | Liver | Healthy |
| PLG | PARD3 | PLG_PARD3 | PARs | Liver | Healthy |
| PLG | F2R | PLG_F2R | PARs | Liver | Precancer |
| PLG | PARD3 | PLG_PARD3 | PARs | Liver | Precancer |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PLG | SNV | Missense_Mutation | novel | c.871N>T | p.Val291Leu | p.V291L | P00747 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-3C-AAAU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | zoladex | SD |
| PLG | SNV | Missense_Mutation | novel | c.1833N>C | p.Leu611Phe | p.L611F | P00747 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| PLG | SNV | Missense_Mutation | novel | c.22C>A | p.Leu8Ile | p.L8I | P00747 | protein_coding | tolerated(0.05) | benign(0.368) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PLG | SNV | Missense_Mutation | c.1993N>C | p.Asp665His | p.D665H | P00747 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| PLG | SNV | Missense_Mutation | novel | c.1670N>C | p.Val557Ala | p.V557A | P00747 | protein_coding | deleterious(0) | benign(0.411) | TCGA-AR-A2LJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| PLG | SNV | Missense_Mutation | novel | c.866T>G | p.Val289Gly | p.V289G | P00747 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PLG | SNV | Missense_Mutation | c.747N>A | p.Asp249Glu | p.D249E | P00747 | protein_coding | tolerated(0.05) | benign(0.167) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PLG | SNV | Missense_Mutation | novel | c.866T>G | p.Val289Gly | p.V289G | P00747 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| PLG | SNV | Missense_Mutation | c.1078G>A | p.Glu360Lys | p.E360K | P00747 | protein_coding | tolerated(0.1) | benign(0.345) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| PLG | SNV | Missense_Mutation | novel | c.288N>T | p.Lys96Asn | p.K96N | P00747 | protein_coding | deleterious(0) | possibly_damaging(0.906) | TCGA-E2-A2P5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | UROKINASE | UROKINASE | ||
| 5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | ALTEPLASE | ALTEPLASE | ||
| 5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | ALTEPLASE | ALTEPLASE | ||
| 5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | DESMOTEPLASE | DESMOTEPLASE | ||
| 5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | Reteplase | RETEPLASE | ||
| 5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | NYSTATIN | NYSTATIN | 7721938 | |
| 5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | ANISTREPLASE | ANISTREPLASE | ||
| 5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | RETEPLASE | RETEPLASE | ||
| 5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | BORTEZOMIB | BORTEZOMIB | 20875739 | |
| 5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | ANTIDEPRESSANTS | 16890384 |
| Page: 1 2 3 4 5 6 7 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |